{"cluster": 62, "subcluster": 21, "abstract_summ": "Although the structure revealed here shares similar overall structure with other published structures, there are several key differences which highlight potential features that could be exploited.Here, we performed molecular docking and molecular dynamics simulations to further characterize the interaction of \u03b1-ketoamide 13b with the active site of the SARS-CoV-2 M(pro).Based on the structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 M(pro).Further, molecular dynamics simulations highlight the stability of the interaction of the \u03b1-ketoamide 13b ligand with the SARS-CoV-2 M(pro) (\u0394G = -25.2 and -22.3 kcal/mol for protomers A and B).Binding to shikonin and binding of covalent inhibitors show different binding modes, suggesting a diversity in inhibitor binding.", "title_summ": "Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikoninX-ray Structure of Main Protease of the Novel Coronavirus SARS-CoV-2 Enables Design of \u03b1-Ketoamide InhibitorsPotential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drugInteraction of the prototypical \u03b1-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complexCrystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors", "title_abstract_phrases": "Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikoninMain protease (Mpro, also known as 3CLpro) has a major role in the replication of coronavirus life cycle and is one of the most important drug targets for anticoronavirus agents.Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitorsThe COVID-19 pandemic caused by SARS-CoV-2 is a global health emergency.Although the structure revealed here shares similar overall structure with other published structures, there are several key differences which highlight potential features that could be exploited.Based on the structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 M(pro).Interaction of the prototypical \u03b1-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complexThe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes an illness known as COVID-19, which has been declared a global pandemic with over 2 million confirmed cases and 137,000 deaths in 185 countries and regions at the time of writing (16 April 2020), over a quarter of these cases being in the United States."}